Articles tagged with Proteasomes
Researchers found a key role for chaperones in protein assembly and regulation of the proteasome's functionality. The study may reveal new targets for anticancer drugs and advance research on Parkinson's and Huntington's diseases.
Researchers at Rockefeller University have identified a new regulator of the proteasome's activity, tankyrase, which uses ADP-ribosylation to modify PI31. This discovery has significant implications for treating multiple myeloma and other diseases, offering a potential therapeutic target.
Researchers at UC Riverside have developed a compound called TIR-199 that targets the proteasome complex in kidney cancer cells, showing promising results in laboratory tests. The compound is nearly as potent as existing bortezomib but selectively inhibits growth of only renal cancer cell lines.
Researchers developed a new testing reaction to identify active agents in mixtures of hundreds of substances. They found two compounds, cepafungin I and glidobactin A, which inhibit the proteasome, causing cancer cells to suffocate on their own waste.
Researchers found that naked mole rats have a greater number of proteasomes and higher protein-disposal activity in liver cells, enabling them to maintain good health. The discovery provides insights into the molecular mechanisms underlying the animal's exceptional ability to resist aging.
Biochemists at TUM have determined the first crystal structure of an immunoproteasome, a specialized protein complex involved in immune defense. The study reveals atomic differences between immunoproteasomes and constitutive proteasomes, enabling the development of new drugs that selectively target the immunoproteasome.
Researchers have elucidated the structure of the 26S proteasome, a key protein degradation machinery, using a combination of structural biology methods. The discovery sheds light on how cells dispose of their waste and could have important implications for understanding neurodegenerative diseases like Alzheimer's and Parkinson's.
A team of researchers has provided the most detailed look ever at the proteasome regulatory particle, a critical component in cellular waste disposal. The study's findings have significant implications for understanding protein quality control and potentially treating diseases like cancer.
Scientists have identified a new class of drugs that target the proteasome in a unique way, leading to potential breakthroughs in cancer medication. The newly discovered hydroxyurea structures work more specifically than existing proteasome inhibitors, reducing severe adverse side effects.
Researchers at RIKEN Brain Science Institute discovered a key mechanism for degrading ubiquitinated protein aggregates in brain cells. This process is mediated by the phosphorylation of p62, which triggers selective autophagy and degradation of protein aggregates.
A study has identified an enzyme called proteasome phosphatase that regulates the removal of damaged proteins from cells. This process is essential for removing misfolded or damaged proteins from the cell, but a defective proteasome can be catastrophic.
Researchers at TUM have developed a new mechanism for reversible proteasome inhibition, which could lead to improved treatments for cancer and immune reactions. By targeting the immuno-proteasome specifically, they aim to minimize damage caused by side effects.
Scientists discovered a key difference in how TB bacteria and human cells deliver unwanted proteins to their respective recycling factories. This critical difference may help design drugs to disable the bacterial system while leaving normal human protein recycling centers intact.
Researchers have discovered a small molecule, IU1, that helps human cells get rid of misfolded proteins implicated in Alzheimer's disease and other neurodegenerative ailments. This potential drug could have applications for other conditions as well.
Researchers have discovered that the harmful amyloid protein in Alzheimer's disease interferes with the cellular process of breaking down proteins, leading to an accumulation of toxic debris. The study reveals a natural mechanism for getting rid of excess amyloid, which may help understand the disease.
Scientists studied Mycobacterium tuberculosis proteasome structure and assembly to understand its role in pathogen survival. This knowledge could aid in developing anti-TB drugs by preventing proteasome maturation.
Researchers at Weill Cornell Medical College have identified new anti-tuberculosis compounds that inhibit the disease-causing bacteria's mechanism for surviving dormant in infected cells. The findings could lead to drugs that destroy TB in its dormant stage, potentially revolutionizing treatment.
Researchers discovered compounds that disable Mycobacterium tuberculosis' proteasome complex, allowing the bacteria to remain dormant. The inhibitors show high specificity for TB microbes while sparing human cells.
Researchers at TUM have developed a custom-tailored anti-cancer drug by understanding the mechanism of proteasome inhibition, a promising approach to treating cancer. By analyzing the reaction pathway and producing variants of the bacteria-produced Salinosporamide A, they aim to create effective drugs with improved safety and efficacy.
A team of scientists has identified two proteins that may act as receptors for autophagosomes, the cell structures responsible for removing misfolded proteins and damaged organelles. This discovery sheds light on how autophagy works and could lead to new drug development.
Chronic ethanol feeding inhibits nuclear proteasome activity, altering epigenetic mechanisms and gene expression. Proteasome inhibition also affects the remethylation pathway, leading to decreased histone acetylation and increased betainehomocysteine methyltransferase (BHMT) enzyme.
The Conaway Lab identifies a new way in which the proteasome helps regulate gene expression through its interaction with the chromatin remodeling complex INO80. This mechanism involves the deubiquitinating enzyme Uch37, which can remove protein tags from other proteins.
Researchers at Goethe University Frankfurt have discovered two gatekeeper proteins, Rpn13 and an ubiquitin receptor, on the proteasome. This finding has significant implications for cancer research, as it may lead to the development of targeted drugs that can block protein breakdown and prevent tumor cell proliferation.
A new study reveals that protein-destroying machines in nerve cells play a crucial role in how memories are formed. The researchers found that blocking activity in these machines could potentially strengthen synapses and improve memory, offering new hope for treating Alzheimer's and other brain diseases.
A new study published in Nature Genetics reveals that diet and lifestyle can significantly impact the effectiveness of certain drugs, including those used for cancer therapies. The research found that nutrient availability can either enhance or harm cell fitness, depending on the surrounding environment.
Researchers at the University of Pennsylvania School of Medicine discovered a molecular link between two major pathways for breaking down proteins in cells. They found that increasing HDAC6 activity can rescue neurodegenerative diseases by facilitating delivery of misfolded proteins to the autophagy-lysosomal system for degradation.
Researchers discover that enhancing proteasome function can recover UPS function and improve cell viability in HD model and patient cells. This breakthrough suggests a potential therapeutic approach to address the underlying protein misfolding disorder of HD.
A study published in JCI found that overexpression of CaMKII altered sodium channel function, leading to increased susceptibility to ventricular tachyarrhythmias in mice. Additionally, proteasome composition differed between Crohn disease and ulcerative colitis, with CD showing increased degradation of an NF-kappa-B inhibitor.
Scientists have made a breakthrough in understanding how Mycobacterium tuberculosis survives within immune cells, revealing a sophisticated protein-cleaning mechanism that could be targeted by new anti-TB drugs. This discovery may lead to effective treatments for TB and potentially eradicate the disease from infected individuals.
A novel proteasome inhibitor, NPI-0052, has been found to block cancer cells' proteasomes, leading to cell death. The compound is distinct from existing therapies like bortezomib and shows promise in preclinical studies.
A Northwestern University team discovered that mutant Huntingtin protein aggregates bind to the proteasome machine, preventing complete degradation of proteins and leading to disease. This interference causes a cumulative negative effect, resulting in the buildup of damaged proteins.
Researchers discover a new class of proteasome inhibitors that change the shape of the protein-digesting enzyme, leading to reduced activity and selective protein degradation. This finding has implications for treating diseases such as heart disease and cancer.
A recent study reveals that estrogen receptors are regularly stripped off DNA to make room for new receptors, enabling cells to continuously sense changes in estrogen levels. This mechanism is essential for the proper functioning of genes and may offer new avenues for therapies in estrogen-related diseases.
Cells utilize an enzyme called the proteasome to remove unnecessary proteins. The study found that the proteasome can independently degrade substrates involved in Parkinson's disease and some types of cancer, producing fragments reminiscent of pathological deposits in Parkinson's patients.
Researchers at Ohio State University and MIT found that a specific protein misfolding in an organelle leads to the transmission of transmissible spongiform encephalopathies. The misfolded proteins accumulate in the cytosol, altering cell metabolism and killing neural cells.
Researchers from the Howard Hughes Medical Institute have pinpointed how light resets the biological clock of fruit flies. By analyzing biochemical consequences of light pulses, they found that light triggers cell breakdown of a key protein called timeless, which is essential for synchronizing the biological to day-night cycle.
The proteasome is a crucial macromolecular machine responsible for eliminating abnormal proteins. It plays a vital role in various biological processes, including the regulation of cell cycle, apoptosis, and immune response. The molecular architecture of the 20S proteasome is conserved from archaea to eukaryotes.